Message

From: Strynar, Mark [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=5A9910D5B38E471497BD875FD329A20A-STRYNAR, MARK]

Sent: 6/17/2019 10:55:44 AM

To: Linnenbrink, Monica [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=01f59a3f644b4c4eb2b74561b4b654d1-Linnenbrink, Monica]; Wetmore,

Barbara [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=1c4254231430480db6d8dc22301ef45c-Wetmore, Ba]

CC: Houck, Keith [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=ed8dcdb7bb474016a3f3a53e54c03a8d-Houck, Keith]

Subject: RE: case study - PFAS

We have sufficient quantities of two on hand.

HFPO-DA (GenX) and PFMOAA.

We can quickly get Nafion BP2 from Synquest labs as it is commercially available now. Nafion BP2 is one of the PFAS found in human serum in Wilmington residents.

Mark

From: Linnenbrink, Monica

Sent: Friday, June 14, 2019 12:08 PM

To: Wetmore, Barbara < wetmore.barbara@epa.gov>

Cc: Houck, Keith <Houck.Keith@epa.gov>; Strynar, Mark <Strynar.Mark@epa.gov>

Subject: Re: case study - PFAS

Ex. 5 Deliberative Process (DP)

Monica

Sent from my iPhone

On Jun 14, 2019, at 12:04 PM, Wetmore, Barbara < wetmore.barbara@epa.gov> wrote:

In hand currently, of the four detected in blood, we have two.

Of the overall case study of ~12 cmpds from Mark's paper, we are trying to ID other sources, and making some headway.

When not available, we are identifying labs that can synthesize; and so far the costs and timelines are pretty reasonable.

Ex. 5 Deliberative Process (DP)

we it have some clarity on that before he's back from his trip.

I was simply providing an FYI that we are collecting this info, rather than giving up altogether on this potential effort. It's not taking too much time, thought it was worth figuring out with we have other options.

From: Linnenbrink, Monica

Sent: Friday, June 14, 2019 11:45 AM **To:** Houck, Keith < Houck. Keith@epa.gov>

Cc: Wetmore, Barbara < wetmore.barbara@epa.gov >; Strynar, Mark < Strynar.Mark@epa.gov >

Subject: Re: case study - PFAS

How many have sufficient quantities and can be screened using high-throughput screening? My recollection is 2.

Monica

Sent from my iPhone

On Jun 14, 2019, at 9:46 AM, Houck, Keith < Houck. Keith@epa.gov > wrote:

What about the ones there is already sufficient quantity available?

From: Linnenbrink, Monica

Sent: Friday, June 14, 2019 9:28 AM **To:** Houck, Keith; Wetmore, Barbara

Cc: Strynar, Mark

Subject: Re: case study - PFAS

Hi Keith and Barbara,

Ex. 5 Deliberative Process (DP)

Monica

Sent from my iPhone

On Jun 14, 2019, at 8:14 AM, Houck, Keith < Houck. Keith@epa.gov > wrote:

I think she needs to use some money on that contract and is trying to make some decisions in the next week or so (not sure of the exact time), so maybe touch base with her as soon as possible. Thanks!

From: Wetmore, Barbara

Sent: Friday, June 14, 2019 8:02 AM **To:** Houck, Keith; Linnenbrink, Monica

Cc: Strynar, Mark

Subject: RE: case study - PFAS

Will do. We are only gathering info; likely will turn over to Ann to handle procurement, etc. if this is the viable way to go. just wanted to start the process.

From: Houck, Keith

Sent: Friday, June 14, 2019 7:58 AM

To: Wetmore, Barbara < wetmore.barbara@epa.gov >; Linnenbrink,

Monica <<u>Linnenbrink.Monica@epa.gov</u>>
Cc: Strynar, Mark <<u>Strynar.Mark@epa.gov</u>>

Subject: Re: case study - PFAS

Okay, thanks. And just remember to keep Ann in the loop to make this work from the database side for testing results, please.

Keith

From: Wetmore, Barbara

Sent: Friday, June 14, 2019 7:49 AM **To:** Houck, Keith; Linnenbrink, Monica

Cc: Strynar, Mark

Subject: RE: case study - PFAS

Hi Keith,

Not actively, per a conversation last week with Monica. We are gathering this info to see if this would be feasible as an alternate strategy. One other concern was that even if we were to get chemicals from Chemours, the quantities offered may not be sufficient to perform the screening we ideally would want to do.

Barbara

From: Houck, Keith

Sent: Friday, June 14, 2019 7:20 AM

To: Wetmore, Barbara < wetmore.barbara@epa.gov >; Linnenbrink,

Monica < Linnenbrink.Monica@epa.gov > Cc: Strynar, Mark < Strynar.Mark@epa.gov >

Subject: Re: case study - PFAS

Barbara--are you still pursuing trying to get samples from Chemours?

thanks, Keith

From: Wetmore, Barbara

Sent: Friday, June 14, 2019 6:34 AM

To: Linnenbrink, Monica

Cc: Houck, Keith; Strynar, Mark **Subject:** case study - PFAS

Hi Monica:

Regarding the chemicals we were discussing assessing with Mark and Keith and potentially others, my SSC has been actively tracking down commercial sources/vendors. Unfortunately some of the more important ones (re: presence in biomonitoring samples) are not commercially available, but he is identifying companies that may be able to synthesize the compounds for us – getting prices and estimated delivery times. Some companies are not the most responsive, so we

don't have a complete listing yet. We should be in good shape by the time I'm back from leave; I can follow up then.

Synthesis costs he's gathered thus far aren't overly unreasonable, nor is delivery time.

Let me know if you have any questions. Mark is cc'ed here as well and is aware of what Lucas has been doing (and advising).

Barbara

Barbara A. Wetmore, Ph.D.

U.S. EPA | Office of Research and Development | National Exposure Research Laboratory

109 T.W. Alexander Drive, MD E243-04; Research Triangle Park, NC 27711

919.541.5433 | E453 | wetmore.barbara@epa.gov